Anticancer Efficacy of Oral Docetaxel Nanoformulation for Metronomic Chemotherapy in Metastatic Lung Cancer
Autor: | Elizabeth Hernandez, Sophia Le, Tina Nguyen, Yuzhou Liu, Jer Tsong Hsieh, Payal Kapur, Chun Mien Chang, Yu-An Chen, Keith P. Johnston, Xiaowei Dong |
---|---|
Rok vydání: | 2020 |
Předmět: |
Lung Neoplasms
Cyclophosphamide 0206 medical engineering Drug availability Biomedical Engineering Pharmaceutical Science Medicine (miscellaneous) Bioengineering Docetaxel 02 engineering and technology Oral administration Antineoplastic Combined Chemotherapy Protocols Animals Humans Medicine General Materials Science Lung business.industry Oral Docetaxel 021001 nanoscience & nanotechnology 020601 biomedical engineering Metronomic Chemotherapy medicine.anatomical_structure Cancer research Metastatic lung cancer Taxoids 0210 nano-technology business medicine.drug |
Zdroj: | Journal of Biomedical Nanotechnology. 16:583-593 |
ISSN: | 1550-7033 |
DOI: | 10.1166/jbn.2020.2925 |
Popis: | Metronomic chemotherapy, giving low doses of chemotherapeutics (e.g., docetaxel) on a frequent schedule over a long time, may improve outcomes and reduce side effects for cancer patients. Oral medications are vital for applying metronomic chemotherapy. However, low solubility, low absorption, low drug availability in the targeted tissue, and side effects limit the development of oral chemotherapeutics. Many chemotherapeutics are intravenously delivered. In this work, we developed a new docetaxel granule that produces docetaxel-loaded in situ self-assembled nanoparticle (180 nm) upon contact with water. The process of manufacturing docetaxel granules is scalable in industrial settings. The lung selectivity of docetaxel granule was observed in animals. The mechanistic studies demonstrated the nanoparticle bound with red blood cells, which selectively delivers docetaxel to the lungs. Finally, docetaxel granule (5 mg/kg twice per week) can profoundly inhibit the tumor growth of lung-metastatic cancer xenograft model over 24 days. The material-based lungselective oral nanoformulation provides an opportunity for conventionally intravenous chemotherapy drugs to be easily applied in oral administration for metronomic chemotherapy for cancer patients with lung cancers. |
Databáze: | OpenAIRE |
Externí odkaz: |